CNSP SEC-arkiveringar - CNS Pharmaceuticals, Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1729427

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CNS Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

August 14, 2025	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
July 22, 2025	EX-3.1	Certificate of Change Exhibit 3.1 Docusign Envelope ID: B31A6C53 - 5172 - 4BAF - 86DE - 27D487A7E369 7/17/2025 Chief Financial Officer
July 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 CNS Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
July 22, 2025	EX-99.1	CNS Pharmaceuticals Announces Reverse Stock Split Exhibit 99.1 CNS Pharmaceuticals Announces Reverse Stock Split HOUSTON, TX (July 18, 2025) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-12 reverse split of its common stock. Beginning on July 22,
July 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 CNS Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
July 15, 2025	EX-99.1	1 NASDAQ: CNSP July 2025 Exhibit 99.1 1 NASDAQ: CNSP July 2025 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives
May 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 CNS Pharmaceuticals, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization
May 15, 2025	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 13, 2025, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s
May 15, 2025	EX-4.2	Form of Pre-Funded Warrant Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: May 14, 2025 Issue Date: May 14, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fo
May 15, 2025	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
May 15, 2025	EX-4.1	Form of Series F Common Warrant Exhibit 4.1 FORM OF SERIES f COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: May 14, 2025 Issue Date: May 14, 2025 THIS SERIES F COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth,
May 15, 2025	EX-1.1	Placement Agent Agreement dated May 13, 2025 by and between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners Exhibit 1.1 May 13, 2025 CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.” or the “Placement Agent”) and CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), that the Placement Agent shall serve as the exclusive place
May 14, 2025	424B4	325,000 Shares of Common Stock 3,627,570 Pre-Funded Warrants to Purchase up to 3,627,570 Shares of Common Stock 3,952,570 Series F Common Warrants to Purchase up to 3,952,570 Shares of Common Stock Up to 3,627,570 Shares of Common Stock Underlying su CNS Pharmaceuticals, Inc. S-1 Filed Pursuant to Rule 424(b)(4) Registration No. 333-286529 Prospectus 325,000 Shares of Common Stock 3,627,570 Pre-Funded Warrants to Purchase up to 3,627,570 Shares of Common Stock 3,952,570 Series F Common Warrants to Purchase up to 3,952,570 Shares of Common Stock Up to 3,627,570 Shares of Common Stock Underlying such Pre-Funded Warrants Up to 3,952,570 Shares of
May 12, 2025	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 May 12, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended (the “Registration Statement”) File No. 333-286529 Ladies and Gentlemen: Purs
May 12, 2025	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 May 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No. 333-286529 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1
May 12, 2025	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) As filed with the Securities and Exchange Commission on May 12, 2025. Registration No. 333-286529 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 2834 82-2318545 (State or Other Jurisdiction of Incorporat
April 30, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
April 17, 2025	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 April 17, 2025 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 April 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Alan Campbell Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration No. 333-286529 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence with the U.
April 17, 2025	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 17, 2025 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-286529 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our letter, filed as
April 14, 2025	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 April 14, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-286529 Ladies and Gentlemen: Pursuant to Ru
April 14, 2025	S-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) As filed with the Securities and Exchange Commission on April 14, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 2834 82-2318545 (State or Other Jurisdiction of Incorporation or Organization) (P
April 14, 2025	EX-4.13	Form of Series F Warrant Exhibit 4.13 FORM OF SERIES f COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS SERIES F COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
April 14, 2025	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 CORRESP 1 filename1.htm A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 14, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-286529 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Secur
April 14, 2025	EX-10.27	Form of Securities Purchase Agreement Exhibit 10.27 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April [] 2025, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
April 14, 2025	EX-1.1	Form of Placement Agency Agreement Exhibit 1.1 April [], 2025 CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.” or the “Placement Agent”) and CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), that the Placement Agent shall serve as the exclusive pla
April 14, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) CNS Pharmaceuticals, Inc.
April 14, 2025	EX-4.14	Form of Pre-Funded Warrant Exhibit 4.14 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
April 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 CNS Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
April 9, 2025	EX-99.1	1 NASDAQ: CNSP April 2025 Exhibit 99.1 1 NASDAQ: CNSP April 2025 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objective
April 7, 2025	EX-4.13	FORM OF SERIES f COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Exhibit 4.13 FORM OF SERIES f COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS SERIES F COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
April 7, 2025	EX-1.1	[Signature Page Follows] Exhibit 1.1 April [], 2025 CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.” or the “Placement Agent”) and CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), that the Placement Agent shall serve as the exclusive pla
April 7, 2025	EX-4.14	FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. EX-4.14 4 filename4.htm Exhibit 4.14 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter s
April 7, 2025	EX-10.27	SECURITIES PURCHASE AGREEMENT EX-10.27 5 filename5.htm Exhibit 10.27 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April [] 2025, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to
April 7, 2025	DRSLTR	ArentFox Schiff LLP ArentFox Schiff LLP 1717 K Street NW Washington, DC 20006 202.857.6000 main 202.857.6395 fax afslaw.com April 7, 2025 CONFIDENTIAL SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7561 Re: CNS Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Confidentially Submitted on April 7, 2025 CIK No. 00017294
April 7, 2025	DRS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Table of Contents As confidentially submitted to the U.S. Securities and Exchange Commission on April 7, 2025. This draft registration statement has not been filed publicly with the U.S. Securities and Exchange Commission and all information contained herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTR
March 31, 2025	EX-19.1	Insider Trading Policy EXHIBIT 19.1 Insider Trading Policy CNS Pharmaceuticals, Inc. Effective March 1, 2022 Table of Contents Introduction 2 Sanctions and Penalties 2 Persons Covered 2 Definition of Material Non-Public Information 2 Requirements Applicable to Everyone 3 No trading in CNS securities while aware of material non-public information 3 Event-specific blackout periods may apply 4 No “tipping” of material non-
March 31, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizati
March 31, 2025	EX-4.1	Description of Securities of CNS Pharmaceuticals, Inc. EXHIBIT 4.1 DESCRIPTION OF THE COMPANY’S SECURITIES The following summary is a description of the material terms of our capital stock. This summary is not complete, and is qualified by reference to our amended and restated articles of incorporation, and our amended and restated bylaws, which are filed as exhibits to this Annual Report on Form 10-K and are incorporated by reference herein. We encou
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39126 CNS Pharma
March 20, 2025	424B5	CNS Pharmaceuticals, Inc. Up to $43,500,000 of Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279285 Supplement No. 2 Prospectus Supplement dated July 26, 2024 (to Prospectus dated May 17, 2024) CNS Pharmaceuticals, Inc. Up to $43,500,000 of Shares of Common Stock This prospectus supplement no. 2, dated March 20, 2025, or this Second Supplement, supplements, modifies, and supersedes, only to the extent indicated herein, certain informat
March 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 CNS Pharmaceutical UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizati
February 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 CNS Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
February 21, 2025	EX-99.1	CNS Pharmaceuticals Announces Reverse Stock Split Exhibit 99.1 CNS Pharmaceuticals Announces Reverse Stock Split HOUSTON, TX (February 19, 2025) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock. Beginning on Febru
January 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 CNS Pharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizat
January 3, 2025	EX-99.1	1 NASDAQ: CNSP January 2025 Forward Looking Statements 2 This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements of historical fact, Exhibit 99.1 1 NASDAQ: CNSP January 2025 Forward Looking Statements 2 This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objecti
December 11, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 CNS Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
December 11, 2024	EX-99.1	1 NASDAQ: CNSP December 11, 2024 Virtual Analyst & Investor Day Exhibit 99.1 1 NASDAQ: CNSP December 11, 2024 Virtual Analyst & Investor Day 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business
December 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 CNS Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
November 15, 2024	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
November 14, 2024	SC 13G/A	CNSP / CNS Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-cnsp093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* CNS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 18978H300 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
November 14, 2024	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September, 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September, 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
November 1, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiza
October 28, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
October 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 CNS Pharmaceutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiza
October 24, 2024	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 23, 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio
October 24, 2024	EX-4.1	Form of Pre-Funded Warrant issued October 23 2024 Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: [•] Initial Exercise Date: October 24, 2024 Issue Date: October 24, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions he
October 24, 2024	EX-99.1	CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules HOUSTON, October 23, 2024 /PRNewswire/ - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nerv
October 24, 2024	EX-1.1	Placement Agency Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners Exhibit 1.1 October 23, 2024 CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.”) (the “Placement Agent”) and CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), that the Placement Agent shall serve as the exclusive pl
October 24, 2024	424B5	CNS Pharmaceuticals, Inc. 3,700,000 Shares of Common Stock Pre-Funded Warrants to Purchase 13,947,060 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279285 Prospectus Supplement (to Prospectus dated May 17, 2024) CNS Pharmaceuticals, Inc. 3,700,000 Shares of Common Stock Pre-Funded Warrants to Purchase 13,947,060 Shares of Common Stock We are offering 3,700,000 shares of our common stock, par value $0.001 per share (the “Shares”) at a price of $0.17 per share, to investors pursuant to this
October 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 CNS Pharmaceutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiza
October 15, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
September 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 CNS Pharmaceut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organi
September 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 CNS Pharmaceut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organi
August 14, 2024	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June, 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June, 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
August 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 CNS Pharmaceutical UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizati
August 2, 2024	SC 13D	CNSP / CNS Pharmaceuticals, Inc. / Cortice Biosciences, Inc. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CNS Pharmaceuticals, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 18978H201 (CUSIP Number) Cortice Biosciences, Inc. 1345 Avenue of the Americas, 42nd Floor New York, NY 10105 (212) 901-1999 (Name, address, and telephone numbers of person author
July 31, 2024	RW	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 July 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration No. 333- 280074 (the “Registration Statement”) Ladies and Gentlemen: Please be advised that the Company hereby requests withdrawal
July 30, 2024	424B3	CNS Pharmaceuticals, Inc. Up to $30,200,000 of Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279285 Prospectus Supplement (to Prospectus dated May 17, 2024) CNS Pharmaceuticals, Inc. Up to $30,200,000 of Shares of Common Stock This Prospectus Supplement, dated July 30, 2024, or this supplement, supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus supplement dated Jul
July 30, 2024	EX-10.1	Exclusive License Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc. Exhibit 10.1 EXCLUSIVE LICENSE AGREEMENT FOR TPI-287 Between CORTICE BIOSCIENCES, INC. AND CNS PHARMACEUTICALS, INC. TABLE OF CONTENTS Page Article 1 Definitions 1 Article 2 Grant 7 2.1 Grant of License 7 2.2 No Implied Licenses; Negative Covenant 7 2.3 Sublicenses 7 Article 3 Technology Transfer 8 3.1 Technology Transfer 8 3.2 Transfer, Assignment and Sale of Compound Inventory and Costs of Trans
July 30, 2024	EX-99.1	CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing poten Exhibit 99.1 CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Drug candidate, TPI 287, a
July 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 CNS Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
July 30, 2024	EX-10.2	Stock Purchase Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc. Exhibit 10.2 STOCK PURCHASE AGREEMENT Between CNS PHARMACEUTICALS, INC., AND CORTICE BIOSCIENCES, INC., Dated: July 29, 2024 Table of Contents Page Article I DEFINITIONS AND RULES OF CONSTRUCTION 1 1.1 Definitions 1 1.2 Rules of Construction 4 Article II PURCHASE AND SALE; CLOSING 5 2.1 Closing 5 2.2 Purchase and Sale 5 2.3 Transactions at the Closing 6 2.4 Issuance under the License 6 Article III
July 30, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
July 26, 2024	EX-1.1	Sales Agreement, dated July 26, 2024, by and between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners Exhibit 1.1 CNS PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENT July 26, 2024 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees
July 26, 2024	EX-10.1	Form of Waiver and Consent Exhibit 10.1 WAIVER AND CONSENT AGREEMENT This Waiver and Consent Agreement dated as of July 25, 2024 (the “Agreement”) is by and between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the undersigned Purchasers (as defined below) identified on the signature pages hereto. Capitalized terms not defined herein shall have the meanings assigned to them in that certain Securities
July 26, 2024	424B5	CNS Pharmaceuticals, Inc. Up to $5,200,000 of Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279285 Prospectus Supplement (to Prospectus dated May 17, 2024) CNS Pharmaceuticals, Inc. Up to $5,200,000 of Shares of Common Stock On July 26, 2024, we entered into a certain Sales Agreement, or sales agreement, with A.G.P./Alliance Global Partners (“A.G.P.”) relating to shares of our common stock offered by this prospectus supplement. In acc
July 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 CNS Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
July 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 CNS Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
July 19, 2024	S-1/A	As filed with the Securities and Exchange Commission on July 19, 2024. Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024.
July 19, 2024	EX-4.18	Form of Series G Common Warrant Exhibit 4.18 FORM OF SERIES G COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS SERIES G COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
July 19, 2024	EX-4.17	Form of Series F Common Warrant Exhibit 4.17 FORM OF SERIES f COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS SERIES F COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
July 12, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) CNS Pharmaceuticals, Inc.
July 12, 2024	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizati
July 12, 2024	S-1	As filed with the Securities and Exchange Commission on July 12, 2024. Table of Contents As filed with the Securities and Exchange Commission on July 12, 2024.
July 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 CNS Pharmaceuticals, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization
July 5, 2024	424B5	CNS Pharmaceuticals, Inc. 1,425,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279285 Prospectus Supplement (to Prospectus dated May 17, 2024) CNS Pharmaceuticals, Inc. 1,425,000 Shares of Common Stock We are offering 1,425,000 shares of our common stock, par value $0.001 per share (the “Shares”) at a price of $1.39 per share, to investors pursuant to this prospectus supplement and the accompanying prospectus, and a secur
July 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 CNS Pharmaceuticals, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization
July 3, 2024	EX-99.1	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement HOUSTON, July 3, 2024 /PRNewswire/ - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has ent
July 3, 2024	EX-4.1	Form of Warrant issued July 3 2024 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 3, 2024	EX-10.2	Financial Advisory Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners Exhibit 10.2 July 3, 2024 CONFIDENTIAL CNS Pharmaceuticals, Inc. Attention: Christopher Downs 2100 West Loop South Suite 900 Houston, TX 77027 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by CNS Pharmaceuticals, Inc. (the “Company”) to render Financial Services (as defined below) to the Company. 1. Se
July 3, 2024	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 3, 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s
June 27, 2024	424B5	CNS Pharmaceuticals, Inc. 568,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279285 Prospectus Supplement (to Prospectus dated May 17, 2024) CNS Pharmaceuticals, Inc. 568,000 Shares of Common Stock We are offering 568,000 shares of our common stock, par value $0.001 per share (the “Shares”) at a price of $2.45 per share, to investors pursuant to this prospectus supplement and the accompanying prospectus, and a securitie
June 26, 2024	EX-99.1	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement HOUSTON, June 26, 2024 /PRNewswire/ - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has en
June 26, 2024	EX-10.2	Financial Advisory Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners Exhibit 10.2 June 26, 2024 CONFIDENTIAL CNS Pharmaceuticals, Inc. Attention: Christopher Downs 2100 West Loop South Suite 900 Houston, TX 77027 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by CNS Pharmaceuticals, Inc. (the “Company”) to render Financial Services (as defined below) to the Company. 1. S
June 26, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
June 26, 2024	EX-4.1	Form of Warrant issued June 26 2024 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 26, 2024	EX-10.1	Form of Securities Purchase Agreement entered into in connection with June 26, 2024, offering Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 26, 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
June 20, 2024	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporat
June 17, 2024	424B5	CNS Pharmaceuticals, Inc. 336,000 Shares of Common Stock Pre-Funded Warrants to Purchase 30,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279285 Prospectus Supplement (to Prospectus dated May 17, 2024) CNS Pharmaceuticals, Inc. 336,000 Shares of Common Stock Pre-Funded Warrants to Purchase 30,000 Shares of Common Stock We are offering 336,000 shares of our common stock, par value $0.001 per share (the “Shares”) at a price of $3.75 per share, to investors pursuant to this prospect
June 14, 2024	EX-4.2	Form of Pre-Funded Warrant issued June 14 2024 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 14, 2024	EX-10.2	Financial Advisory Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners Exhibit 10.2 June 14, 2024 CONFIDENTIAL CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South Suite 900 Houston, TX 77027 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by CNS Pharmaceuticals, Inc. (the “Company”) to render Financial Services (as defined below) to the Company. 1. Servic
June 14, 2024	EX-4.1	Form of Warrant issued June 14 2024 Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
June 14, 2024	EX-99.1	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement HOUSTON, June 14, 2024 /PRNewswire/ - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has en
June 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 CNS Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
June 14, 2024	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 14, 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
June 10, 2024	EX-4.13	Form of Pre-Funded Warrant Exhibit 4.13 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
June 10, 2024	S-1	As filed with the Securities and Exchange Commission on June 7, 2024. Table of Contents As filed with the Securities and Exchange Commission on June 7, 2024.
June 10, 2024	EX-1.1	Form of Placement Agent Agreement Exhibit 1.1 June [], 2024 CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.”), Brookline Capital Markets, a division of Arcadia Securities. LLC (“Brookline” and together with A.G.P., the “Placement Agents”) and CNS Pharmaceuticals
June 10, 2024	EX-4.15	Form of Series D Common Warrant Exhibit 4.15 FORM OF SERIES D COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS SERIES D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
June 10, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) CNS Pharmaceuticals, Inc.
June 10, 2024	EX-4.14	Form of Series C Common Warrant Exhibit 4.14 FORM OF SERIES C COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
June 10, 2024	EX-10.23	Form of Securities Purchase Agreement Exhibit 10.23 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June [] 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
June 5, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization
June 5, 2024	EX-3.1	Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada Exhibit 3.1 Business Number E0354342017 - 0 Filed in the Office of Secretary of State State Of Nevada Filing Number 20244102253 Filed On 6/3/2024 9:44:00 AM Number of Pages 2 DocuSign Envelope ID: 263E7B1B - E7O1 - 4C2E - A518 - 83O839E7FDEF FRANCISCO V. AGUILAR Secretary of State 202 North Carson Street Carson City, Nevada 89701 - 4201 (775) 684 - 5708 Website: www . nvsos.gov Profit Corporation:
June 5, 2024	EX-99.1	CNS Pharmaceuticals Announces Reverse Stock Split Exhibit 99.1 CNS Pharmaceuticals Announces Reverse Stock Split HOUSTON, TX (June 3, 2024) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET
May 16, 2024	EX-99.1	CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025 Company committed to addressing the most aggressive type of brain Exhibit 99.1 CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025 Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX (May 16, 2024) – CNS Pharmaceuticals, In
May 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 CNS Pharmaceuticals, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization
May 15, 2024	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March, 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 1 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March, 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
May 15, 2024	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 May 15, 2024 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 May 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Lauren Hamill Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-3 Registration No. 333-279285 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Ph
May 9, 2024	EX-4.2	Form of Subordinated Indenture Exhibit 4.2 CNS PHARMACEUTICALS, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 DEFINITIONS 1 SECTION 1.2 COMPLIANCE CERTIFICATES AND OPINIONS 8 SECTION 1.3 FORM OF DOCUMENTS DELIVERED TO TRUSTEE 8 SECTION 1.4 ACTS OF HOLDERS; RECORD DATES 9 SECTION 1.5 NOTICES, ETC., TO TRUSTEE AND COMPANY
May 9, 2024	EX-4.1	Form of Unsubordinated Indenture Exhibit 4.1 CNS PHARMACEUTICALS, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 DEFINITIONS 1 SECTION 1.2 COMPLIANCE CERTIFICATES AND OPINIONS 7 SECTION 1.3 FORM OF DOCUMENTS DELIVERED TO TRUSTEE 8 SECTION 1.4 ACTS OF HOLDERS; RECORD DATES 8 SECTION 1.5 NOTICES, ETC., TO TRUSTEE AND COMPANY 10 SEC
May 9, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) CNS Pharmaceuticals, Inc.
May 9, 2024	S-3	As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.
May 7, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization)
May 3, 2024	EX-10.1	2020 Stock Plan of CNS Pharmaceuticals, Inc. (as amended) Exhibit 10.1 CNS PHARMACEUTICALS, INC. 2020 EQUITY PLAN (Amended and Restated) Section 1. Establishment and Purpose. 1.1The Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) established the CNS Pharmaceuticals, Inc. 2020 Equity Plan (the “Plan”) effective as of April 6, 2020, which was approved by the Company’s stockholders at the Company’s annual meeting on June 8, 2020. The Plan wa
May 3, 2024	EX-3.1	Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada Exhibit 3.1 TEXT OF CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF CNS PHARMACEUTICALS, INC. Section 3.1 of the Amended and Restated Articles of Incorporation is amended and restated as follows: 3.1. The Corporation shall have the authority to issue 300,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”).
May 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 CNS Pharmaceutical UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizati
April 15, 2024	EX-99.1	INVESTOR PRESENTATION April 2024 www.CNSPharma.com NASDAQ: CNSP NASDAQ: CNSP This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements Exhibit 99.1 INVESTOR PRESENTATION April 2024 www.CNSPharma.com NASDAQ: CNSP NASDAQ: CNSP This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and pl
April 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 CNS Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
April 10, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39126 CNS Pharma
April 1, 2024	EX-97.0	CNS Pharmaceuticals, Inc. Restatement Recoupment Policy Exhibit 97 CNS Pharmaceuticals, Inc. Dodd-Frank Restatement Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of CNS Pharmaceuticals, Inc. (the “Company”) has determined that it is in the best interests of the Company to adopt a policy providing for the recoupment by the Company of certain Incentive-Based Compensation paid to Executives Officers in the case of a Restatement (a
April 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizatio
April 1, 2024	EX-99.1	CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proce Exhibit 99.1 CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM study Berubicin study enrollment completed; Topline data expected in first half of 202
March 28, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
February 27, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
February 21, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
February 14, 2024	SC 13G/A	CNSP / CNS Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-cnsp123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CNS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 18978H201 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
February 2, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiza
February 2, 2024	EX-4.2	Form of Series B Common Warrant issued January 2024 Exhibit 4.2 FORM OF SERIES B COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: February 1, 2024 Issue Date: February 1, 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se
February 2, 2024	EX-1.1	Placement Agent Agreement dated January 29, 2024 by and among CNS Pharmaceuticals, Inc., A.G.P./Alliance Global Partners and Maxim Group LLC Exhibit 1.1 January 29, 2024 CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.”), Maxim Group LLC (“Maxim” and together with A.G.P., the “Placement Agents”) and CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), that
February 2, 2024	EX-4.3	Form of Pre-Funded Warrant issued January 2024 Exhibit 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: February 1, 2024 Issue Date: February 1, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafte
February 2, 2024	EX-10.2	Form of Amendment to Common Stock Purchase Warrants Exhibit 10.2 AMENDMENT TO COMMON STOCK PURCHASE WARRANTS This AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of January 29, 2024, by and between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and (the “Holder”). WHEREAS, the Holder is the holder of a Common Stock Purchase Warrant issued on October 16, 2023 (the “October 2023 Warrant”) to purchas
February 2, 2024	EX-4.1	Form of Series A Common Warrant issued January 2024 Exhibit 4.1 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: February 1, 2024 Issue Date: February 1, 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se
February 2, 2024	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 29, 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio
January 31, 2024	424B4	2,215,667 Shares of Common Stock 11,117,667 Pre-Funded Warrants to Purchase up to 11,117,667 Shares of Common Stock 13,333,334 Series A Common Warrants to Purchase up to 13,333,334 Shares of Common Stock 13,333,334 Series B Common Warrants to Purchas Prospectus Filed Pursuant to Rule 424(b)(4) Registration No. 333-275973 2,215,667 Shares of Common Stock 11,117,667 Pre-Funded Warrants to Purchase up to 11,117,667 Shares of Common Stock 13,333,334 Series A Common Warrants to Purchase up to 13,333,334 Shares of Common Stock 13,333,334 Series B Common Warrants to Purchase up to 13,333,334 Shares of Common Stock 11,117,667 Shares of Common Stock Un
January 26, 2024	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 January 25, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Pursuant to
January 26, 2024	CORRESP	A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 January 25, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. Registration Statement on Form S-1, as amended File No: 333-275973 Ladies and Gentlemen: Pursuant to Rule 461 promulgated unde
January 25, 2024	CORRESP	A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 January 25, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-275973) (the “Registration Statement”) Ladies and Gentlemen:
January 25, 2024	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 January 25, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Reference is
January 24, 2024	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 January 24, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. Registration Statement on Form S-1, as amended File No: 333-275973 Ladies and Gentlemen: Pursuant to Rule 461 promulgated un
January 24, 2024	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 January 24, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Pursuant to
January 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 CNS Pharmaceutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiza
January 22, 2024	EX-4.12	Form of Series B Common Warrant Exhibit 4.12 FORM OF SERIES B COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
January 22, 2024	S-1/A	As filed with the Securities and Exchange Commission on January 22, 2024. Table of Contents As filed with the Securities and Exchange Commission on January 22, 2024.
January 22, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) CNS Pharmaceuticals, Inc.
January 22, 2024	EX-4.11	Form of Series A Common Warrant Exhibit 4.11 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
January 22, 2024	EX-10.22	Form of Securities Purchase Agreement Exhibit 10.22 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set
January 18, 2024	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 January 18, 2024 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 January 18, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re:     CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Referenc
January 18, 2024	CORRESP	A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 January 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-275973) (the “Registration Statement”) Ladies and Gentlemen:
January 16, 2024	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 January 16, 2024 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 January 16, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re:     CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Pursuant
January 16, 2024	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 January 16, 2024 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 January 16, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. Registration Statement on Form S-1, as amended Filed January 10, 2024 File No: 333-275973 Ladies and Gentlemen: Pursuant to
January 10, 2024	S-1/A	As filed with the Securities and Exchange Commission on January 10, 2024. Table of Contents As filed with the Securities and Exchange Commission on January 10, 2024.
December 26, 2023	CORRESP	A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 26, 2023 A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 26, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-275973) (the “Registration Statement”) Ladies and Gentlemen:
December 26, 2023	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 26, 2023 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 26, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Reference i
December 21, 2023	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 21, 2023 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 21, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Pursuant to
December 21, 2023	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 21, 2023 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 21, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Reference i
December 21, 2023	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 21, 2023 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 21, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. Registration Statement on Form S-1 Filed December 8, 2023 File No: 333-275973 Ladies and Gentlemen: Pursuant to Rule 461 pr
December 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 CNS Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
December 21, 2023	CORRESP	A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 21, 2023 A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 21, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-275973) (the “Registration Statement”) Ladies and Gentlemen:
December 20, 2023	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 20, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Reference is made to our letter,
December 20, 2023	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 20, 2023 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 20, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. Registration Statement on Form S-1 Filed December 8, 2023 File No: 333-275973 Ladies and Gentlemen: Pursuant to Rule 461 pr
December 20, 2023	CORRESP	A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 20, 2023 A.G.P./Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 20, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-275973) (the “Registration Statement”) Ladies and Gentlemen:
December 20, 2023	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 20, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Pursuant to
December 18, 2023	EX-99.1	CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin Independent DSMB recommends continuing clinical trial of Berubicin without modification Enrollment expected to be complete Exhibit 99.1 CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin Independent DSMB recommends continuing clinical trial of Berubicin without modification Enrollment expected to be complete in early Q1 2024 HOUSTON, TX (December 18, 2023) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (CNS or the Company), a biopharmaceutical co
December 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 CNS Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
December 14, 2023	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 14, 2023 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 December 14, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals Inc. Registration Statement on Form S-1 Filed December 8, 2023 File No: 333-275973 Ladies and Gentlemen: Pursuant to Rule 461 pr
December 14, 2023	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 14, 2023 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 December 14, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Pursuant to
December 8, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) CNS Pharmaceuticals, Inc.
December 8, 2023	EX-4.11	Form of Common Warrant Exhibit 4.11 FORM OF COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [] (the “Ini
December 8, 2023	EX-10.22	Form of Securities Purchase Agreement Exhibit 10.22 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December [], 2023, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit
December 8, 2023	EX-1.1	Form of Placement Agent Agreement Exhibit 1.1 December [], 2023 CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.”), Maxim Group LLC (“Maxim” and together with A.G.P., the “Placement Agents”) and CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), tha
December 8, 2023	S-1	As filed with the Securities and Exchange Commission on December 8, 2023. Table of Contents As filed with the Securities and Exchange Commission on December 8, 2023.
December 8, 2023	EX-4.10	Form of Pre-Funded Warrant Exhibit 4.10 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: [] Issue Date: [] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
November 30, 2023	424B3	CNS Pharmaceuticals, Inc. 3,756,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275671 PROSPECTUS CNS Pharmaceuticals, Inc. 3,756,000 Shares of Common Stock This prospectus covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggregate of 3,756,000 shares of our common stock issuable upon exercise of inducement warrants to purchase 3,756,000 shares of our common stock (the “Induc
November 28, 2023	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 November 28, 2023 CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 November 28, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Tyler Howes Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-3 Registration No. 333-275671 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS
November 22, 2023	S-8	As filed with the Securities and Exchange Commission on November 21, 2023 As filed with the Securities and Exchange Commission on November 21, 2023 Registration No.
November 22, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CNS Pharmaceuticals, Inc (Exact Name of Registrant as Specified in its Charter) Table 1-Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.
November 20, 2023	S-3	As filed with the Securities and Exchange Commission on November 20, 2023 As filed with the Securities and Exchange Commission on November 20, 2023 Registration No.
November 20, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) CNS Pharmaceuticals, Inc.
November 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 CNS Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
November 15, 2023	EX-99.1	CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Enrollment numbers rise to 239 in ongoing potentially pivotal study of Exhibit 99.1 CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment in December 2023 - Topline data from preplanned interim analysis from ongoing B
November 14, 2023	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
October 18, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiza
October 17, 2023	EX-4.1	Form of Inducement Warrant issued in October 2023 offering Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 17, 2023	EX-10.1	Form of Inducement Letter Exhibit 10.1 CNS PHARMACEUTICALS, INC. 2100 West Loop South, Suite 900 Houston, Texas 77027 October 16, 2023 To: Re:Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: CNS Pharmaceuticals, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new warrants to purchase up to shares of the Company’s common
October 17, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiza
September 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 CNS Pharmaceut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organi
September 19, 2023	EX-10.1	2020 Stock Plan of CNS Pharmaceuticals, Inc. (as amended September 14, 2023) Exhibit 10.1 CNS PHARMACEUTICALS, INC. 2020 EQUITY PLAN (Amended and Restated) Section 1. Establishment and Purpose. 1.1 The Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) established the CNS Pharmaceuticals, Inc. 2020 Equity Plan (the “Plan”) effective as of April 6, 2020, which was approved by the Company’s stockholders at the Company’s annual meeting on June 8, 2020. The Plan w
August 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 CNS Pharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizat
August 15, 2023	EX-3.1	Amended and Restated Bylaws of CNS Pharmaceuticals, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CNS PHARMACEUTICALS, INC. ARTICLE I—OFFICES Section 1.01 Registered Office. The corporation shall maintain in the State of Nevada a registered office and a registered agent whose business office is identical with such registered office. Section 1.02 Locations of Offices. The corporation may also have offices at such other places both within and without th
August 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 CNS Pharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizat
August 14, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
August 14, 2023	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
August 14, 2023	EX-99.1	CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for the trea Exhibit 99.1 CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM Topline data from interim analysis from ongoing Berubicin potentially pivotal study on track before year end HOUSTON, TX (Au
August 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 CNS Pharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizat
August 1, 2023	SC 13G	CNSP / Cns Pharmaceuticals Inc / Priebe Waldemar Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) CNS Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 18978H201 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
May 15, 2023	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
May 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 CNS Pharmaceuticals, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization
May 15, 2023	EX-99.1	CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment in ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM continues to rapidly progress toward planned interim analysis Exhibit 99.1 CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment in ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM continues to rapidly progress toward planned interim analysis, expected in the third quarter of 2023 HOUSTON, TX (May 15, 2023) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a
May 8, 2023	EX-99.1	Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors Brings over 30 years of significant biopharmaceutical industry experience and proven clinical development and operational exp Exhibit 99.1 Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors Brings over 30 years of significant biopharmaceutical industry experience and proven clinical development and operational expertise across multiple therapeutic disciplines worldwide HOUSTON, TX (May 8, 2023) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or t
May 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 CNS Pharmaceuticals, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization)
May 1, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39126 CNS Pharma
February 14, 2023	SC 13G	US18978H2013 / CNS PHARMACEUTICALS INC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-cnsp123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CNS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 18978H201 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
January 3, 2023	EX-99.1	CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors Exhibit 99.1 CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations HOUSTON, TX (January 3, 2023) ? CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (?CNS? or the ?Company?), a biopharmaceutical company special
January 3, 2023	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
December 14, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
December 5, 2022	424B4	147,000 Shares of Common Stock and Accompanying Common Warrants to Purchase up to 1,889,764 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 1,742,764 Shares of Common Stock Shares of Common Stock underlying the Prefunded Warrants and Com Table of Contents Prospectus Filed Pursuant to Rule 424(b)(4) Registration No. 333-267975 147,000 Shares of Common Stock and Accompanying Common Warrants to Purchase up to 1,889,764 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 1,742,764 Shares of Common Stock Shares of Common Stock underlying the Prefunded Warrants and Common Warrants Placement Agent Warrants to Purchase Up to 94,4
December 1, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 CNS Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
December 1, 2022	EX-99.1	CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price Exhibit 99.1 CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price HOUSTON, TX (November 30, 2022) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the
December 1, 2022	EX-10.3	Form of Warrant Amendment Agreement Exhibit 10.3 November 30, 2022 Holder of Warrants to Purchase Common Stock issued on December 28, 2020 and January 10, 2022 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the concurrent public offering on or about the date hereof (the “Offering”) by CNS Pharmaceuticals, Inc. (the “Company”) of its securities (collectively, the “Securities”). This letter confirms that,
December 1, 2022	EX-4.2	Form of Pre-Funded Warrant Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: December 5, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
December 1, 2022	EX-4.1	Form of Warrant. Exhibit 4.1 COMMON STOCK PURCHASE WARRANT CNS Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: [ ], 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial
December 1, 2022	EX-10.2	Form of Placement Agency Agreement Exhibit 10.2 PLACEMENT AGENCY AGREEMENT November 30, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $6,000,000of registered securities of the Company, including, but
December 1, 2022	EX-4.3	Form of Placement Agent Warrant Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT CNS Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: December 5, 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
December 1, 2022	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 30, 2022, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi
November 28, 2022	EX-99.1	CNS Pharmaceuticals Announces Reverse Stock Split Exhibit 99.1 CNS Pharmaceuticals Announces Reverse Stock Split HOUSTON, TX (November 28, 2022) ? CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (?CNS? or the ?Company?), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-30 reverse split of its common stock, effective at 4:01
November 28, 2022	CORRESP	430 Park Avenue \| New York, NY 10022 \| 212.356.0500 \| www.hcwco.com Member: FINRA/SIPC CORRESP 1 filename1.htm November 28, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-267975) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in
November 28, 2022	CORRESP	CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 November 28, 2022 CORRESP 1 filename1.htm CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 November 28, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Doris Stacey Gama Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration No. 333-267975 Ladies and Gentlemen: Pursuant to Rule 461 of the Securitie
November 28, 2022	S-1/A	As filed with the Securities and Exchange Commission on November 28, 2022. Table of Contents As filed with the Securities and Exchange Commission on November 28, 2022.
November 28, 2022	EX-3.1	Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada Exhibit 3.1 Filed in the Office of Secretary of State State Of Nevada Business Number E0354342017 - 0 Filing Number 20222774072 Filed On 11/23/2022 11:09:00 AM Number of Pages 3 1 DocuSign Envelope ID: 8C66BEE3 - B5EA - 45DE - B7E3 - EFA268059255 ,:.. \ ,i' - . ?." ,..I/ ) t . . .... . . .? '';,,'V,:c.,, BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701 - 420
November 28, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiz
November 15, 2022	EX-4.8	Form of Common Warrant issued in November 2023 offering Exhibit 4.8 COMMON STOCK PURCHASE WARRANT CNS Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: [ ], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial
November 15, 2022	EX-4.7	Form of Pre-Funded Warrant issued in November 2022 offering Exhibit 4.7 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CNS Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: [ ], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the dat
November 15, 2022	S-1/A	As filed with the Securities and Exchange Commission on November 15, 2022. Table of Contents As filed with the Securities and Exchange Commission on November 15, 2022.
November 15, 2022	EX-4.9	Form of Placement Agent Warrant issued in November 2023 offering Exhibit 4.9 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT CNS Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: [ ], 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft
November 15, 2022	EX-10.21	Form of Placement Agent Agreement in November 2023 offering Exhibit 10.21 PLACEMENT AGENCY AGREEMENT November [], 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this ?Agreement?), CNS Pharmaceuticals, Inc., a Nevada corporation (the ?Company?), hereby agrees to sell up to an aggregate of $[] of registered securities of the Company, including, but not l
November 15, 2022	CORRESP	* * * November 15, 2022 ArentFox Schiff LLP 901 K Street NW Suite 700 Washington, DC 20006 202.
November 15, 2022	EX-10.20	Form of Securities Purchase Agreement Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2022, between CNS Pharmaceuticals, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set fo
November 10, 2022	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39126 CNS Pharmaceuticals, Inc.
October 24, 2022	EX-99.1	Prospectus Summary Exhibit 99.1 Prospectus Summary This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the ?Risk Factors? section in this prospectus and under similar captions in the documents incorporated by ref
October 24, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organiza
October 21, 2022	S-1	As filed with the Securities and Exchange Commission on October 21, 2022. Table of Contents As filed with the Securities and Exchange Commission on October 21, 2022.
October 21, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 cnsex107.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate O
August 26, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizat
August 19, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizat
August 16, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizat
August 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organizat
August 15, 2022	EX-99.1	CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Continued execution on clinical operations for potentially pivotal global trial evaluating Berubicin for the treatment of Glioblastoma Multiforme (“GBM”) Exhibit 99.1 CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Continued execution on clinical operations for potentially pivotal global trial evaluating Berubicin for the treatment of Glioblastoma Multiforme (?GBM?) Enrollment progressing with 23 clincal trial sites open to-date of the 54 sites selected across the U.S., Italy, France, Spain, and Switz

CNSP / CNS Pharmaceuticals, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)

Other Listings